ReachMD

ReachMD CME

Science EN ↓ Odcinki: 408

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Koniecznie odwiedź stronę podcastu i wesprzyj twórcę: reachmd.com

Autor

ReachMD

Kategoria

Science

Strona podcastu

reachmd.com

Ostatni odcinek

23 cze 2026

Gdzie słuchać?

Podcasty w aplikacji Replaio Radio Już wkrótce

Podcasty trafią do aplikacji już wkrótce. Zainstaluj teraz i jako pierwszy zobacz nowe podejście do podcastów

Zainstaluj za darmo Android prawie 10 mln pobrań · ocena 4,8 iOS niedługo

Odcinki

Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025 26.09.2025 4:30

CME credits: 0.50 Valid until: 11-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-clinical-evidence-for-b7-h3directed-adcs-in-es-sclc-from-esmo-2025/39978/ This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological ration...

Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC 26.09.2025 4:15

CME credits: 0.50 Valid until: 11-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-criteria-and-imaging-strategies-for-b7-h3directed-adcs-in-es-sclc/39977/ This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationa...

Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 26.09.2025 5:15

CME credits: 0.50 Valid until: 11-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/translating-clinical-data-into-multidisciplinary-practice-for-es-sclc/37878/ This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale fo...

Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025 26.09.2025 5:30

CME credits: 0.50 Valid until: 11-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-clinical-evidence-for-b7-h3directed-adcs-in-es-sclc-from-wclc-2025/37877/ This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological ration...

Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 26.09.2025 4:30

CME credits: 0.50 Valid until: 11-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/rethinking-the-therapeutic-targeting-of-b7-h3-in-es-sclc/37876/ This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B...

From Resistance to Response: Evolving Strategies in MDD Management 26.09.2025 57:45

CME credits: 1.00 Valid until: 26-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/from-resistance-to-response-evolving-strategies-in-mdd-management/32847/ Can you recognize the symptoms of major depressive disorder? Do you know when to augment and when to switch therapies? Join our experts for these answers and learn about novel treatments on the horizon. Don’t miss this opportun...

Future Directions in Managing Hyperkalemia in CKD and HF 24.09.2025 7:00

CME credits: 1.00 Valid until: 24-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/tbd/37676/ Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (R...

Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders 24.09.2025 5:00

CME credits: 1.00 Valid until: 24-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/tbd/37675/ Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (R...

Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up 24.09.2025 7:00

CME credits: 1.00 Valid until: 24-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/tbd/37674/ Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (R...

Potassium Binders: Safety Comes First! 24.09.2025 7:45

CME credits: 1.00 Valid until: 24-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/tbd/37673/ Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (R...

Potassium Binders in Practice: Clinical Trial Evidence 24.09.2025 6:00

CME credits: 1.00 Valid until: 24-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/tbd/37672/ Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (R...

Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF 24.09.2025 4:30

CME credits: 1.00 Valid until: 24-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/tbd/37671/ Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (R...

Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment 24.09.2025 5:45

CME credits: 1.00 Valid until: 24-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/tbd/37670/ Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (R...

Guidelines Update: RAASi/MRA Therapy in CKD and HF Management 24.09.2025 5:30

CME credits: 1.00 Valid until: 24-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/tbd/36194/ Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (R...

The Critical Interplay: CKD, HF, and HyperkaleAmia 24.09.2025 4:15

CME credits: 1.00 Valid until: 24-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-critical-interplay-ckd-hf-and-hyperkalemia/36193/ Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–a...

Bronchiectasis Update: Diagnostic Innovations and Therapeutic Frontiers 19.09.2025 53:30

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/bronchiectasis-update-diagnostic-innovations-and-therapeutic-frontiers/37233/ Bronchiectasis is complex, often underdiagnosed, and frequently misunderstood. Explore key contributors to disease progression, including the role of neutrophilic inflammation and neutrophilic serine proteases, and learn t...

Future Directions in FSGS Care 19.09.2025 7:00

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/future-directions-in-fsgs-care/37191/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. B...

Integrating the Patient Voice in FSGS Management 19.09.2025 6:15

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/integrating-the-patient-voice-in-fsgs-management/37190/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals fo...

Treatment Considerations for Pediatric Patients With FSGS 19.09.2025 5:30

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/treatment-considerations-for-pediatric-patients-with-fsgs/37189/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment...

DEARA Versus SOC in FSGS Management: Clinical Trial Insights 19.09.2025 6:00

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/deara-versus-soc-in-fsgs-management-clinical-trial-insights/37188/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatme...

Monitoring FSGS: Traditional and Novel Biomarkers 19.09.2025 5:30

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/monitoring-fsgs-traditional-and-novel-biomarkers/37187/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals fo...

Emerging Therapies in Managing Adult and Pediatric Patients With FSGS: Latest Data 19.09.2025 5:45

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapies-in-managing-adult-and-pediatric-patients-with-fsgs-latest-data/37186/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therap...

FSGS: Interpretation of Proteinuria Reduction Thresholds 19.09.2025 5:45

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/fsgs-interpretation-of-proteinuria-reduction-thresholds/37185/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment g...

Current FSGS Treatment Landscape: More Questions Than Answers 19.09.2025 5:15

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/current-fsgs-treatment-landscape-more-questions-than-answers/37184/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatm...

FSGS: When Solutions Fall Short 19.09.2025 6:00

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/fsgs-when-solutions-fall-short/37183/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. B...